Akira Abe
age ~71
from Ann Arbor, MI
Akira Abe Phones & Addresses
- 1125 Nielsen Ct APT 4, Ann Arbor, MI 48105 • 7344767691
- 1140 Nielsen Ct, Ann Arbor, MI 48105 • 7346620996
- 1125 Nielsen Ct APT 4, Ann Arbor, MI 48105 • 7346620996
Work
-
Position:Machine Operators, Assemblers, and Inspectors Occupations
Education
-
Degree:Graduate or professional degree
Isbn (Books And Publications)
Us Patents
-
Methods And Compositions For Using Alveolar Macrophage Phospholipase A2
view source -
US Patent:7319015, Jan 15, 2008
-
Filed:Apr 28, 2005
-
Appl. No.:11/117161
-
Inventors:James A. Shayman - Ann Arbor MI, US
Akira Abe - Ann Arbor MI, US
Miki Hiraoka - Ann Arbor MI, US -
Assignee:The Regents of The University of Michigan - Ann Arbor MI
-
International Classification:C12Q 1/42
-
US Classification:435 21, 435198, 424 946
-
Abstract:The present invention is directed to methods and compositions for improving pulmonary surfactant catabolism. More specifically, the specification describes methods and compositions for making and using a lysosomal phospholipase A2 in methods for the diagnosis, and treatment of disorders of phospholipid catabolism such as pulmonary alveolar proteinosis.
-
Methods And Compositions For Using Aleveolar Macrophage Phospholipase A2
view source -
US Patent:7582442, Sep 1, 2009
-
Filed:Mar 15, 2005
-
Appl. No.:11/080257
-
Inventors:James A. Shayman - Ann Arbor MI, US
Akira Abe - Ann Arbor MI, US
Miki Hiraoka - Ann Arbor MI, US -
Assignee:The Regents of the University of Michigan - Ann Arbor MI
-
International Classification:C12Q 1/42
-
US Classification:435 21, 435198, 424 946
-
Abstract:The present invention is directed to methods and compositions for improving pulmonary surfactant catabolism. More specifically, the specification describes methods and compositions for making and using a lysosomal phospholipase A2 in methods for the diagnosis, and treatment of disorders of phospholipid catabolism such as pulmonary alveolar proteinosis.
-
Lysosomal Phospholipase A2 (Lpla2) Activity As A Diagnostic And Therapeutic Target For Identifying And Treating Systemic Lupus Erythematosis
view source -
US Patent:8052970, Nov 8, 2011
-
Filed:Jun 30, 2009
-
Appl. No.:12/495209
-
Inventors:James A. Shayman - Ann Arbor MI, US
Akira Abe - Ann Arbor MI, US
Robert Kelly - Trenton MI, US
Jessica Kollmeyer - Ypsilanti MI, US
Ye Lu - Ann Arbor MI, US -
Assignee:The Regents of the University of Michigan - Ann Arbor MI
-
International Classification:A61K 38/46
-
US Classification:424 946, 424 94, 435375, 435 19
-
Abstract:The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
-
Lysosomal Phospholipase A2 (Lpla2) Activity As A Diagnostic And Therapeutic Target For Identifying And Treating Systemic Lupus Erythematosis
view source -
US Patent:20120121571, May 17, 2012
-
Filed:Oct 13, 2011
-
Appl. No.:13/272949
-
Inventors:James A. Shayman - Ann Arbor MI, US
Akira Abe - Ann Arbor MI, US
Robert Kelly - Trenton MI, US
Jessica Kollmeyer - Ypsilanti MI, US
Ye Lu - Ann Arbor MI, US -
Assignee:THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI
-
International Classification:A61K 38/46
A61P 29/00 -
US Classification:424 946
-
Abstract:The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
-
Glucosylceramide Synthase Inhibitors And Therapeutic Methods Using The Same
view source -
US Patent:20130095089, Apr 18, 2013
-
Filed:Oct 15, 2012
-
Appl. No.:13/652016
-
Inventors:The Regents of The University of Michigan - Ann Arbor MI, US
Akira Abe - Ann Arbor MI, US
Liming Shu - Ann Arbor MI, US
Michael William Wilson - Ann Arbor MI, US
Richard F. Keep - Ann Arbor MI, US
James A. Shayman - Ann Arbor MI, US -
Assignee:The Regents of The University of Michigan - Ann Arbor MI
-
International Classification:A61K 31/4025
C07D 207/09
A61K 31/40
A61P 25/16
A61P 25/00
A61K 48/00
A61P 7/06
A61P 35/00
A61P 13/12
A61P 9/10
A61P 31/00
A61K 38/43
C07D 405/10
A61P 3/10 -
US Classification:424 941, 548526, 514422, 548569, 514428, 548568, 514 44 R
-
Abstract:Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthase provides a benefit, like Gaucher disease and Fabry disease, also are disclosed.
-
Glucosylceramide Synthase Inhibitors And Therapeutic Methods Using The Same
view source -
US Patent:20180022697, Jan 25, 2018
-
Filed:Feb 1, 2016
-
Appl. No.:15/546320
-
Inventors:- Ann Arbor MI, US
Akira Abe - Ann Arbor MI, US
Liming Shu - Ann Arbor MI, US
Michael William Wilson - Ann Arbor MI, US
Richard F. Keep - Ann Arbor MI, US
Duxin Sun - Ann Arbor MI, US
James A. Shayman - Ann Arbor MI, US -
International Classification:C07D 207/06
C07D 263/20
C07D 207/10
C07D 295/13
C07D 205/04 -
Abstract:Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthase provides a benefit, like Gaucher disease and Fabry disease, also are disclosed.
-
Lysosomal Phospholipase A2 (Lpla2) Activity As A Diagnostic And Therapeutic Target For Identifying And Treating Systemic Lupus Erythematosus
view source -
US Patent:20160317626, Nov 3, 2016
-
Filed:Apr 11, 2016
-
Appl. No.:15/095685
-
Inventors:- Ann Arbor MI, US
Akira Abe - Ann Arbor MI, US
Robert Kelly - Trenton MI, US
Jessica Kollmeyer - Ypsilanti MI, US
Ye Lu - Ann Arbor MI, US -
International Classification:A61K 38/45
G01N 33/68 -
Abstract:The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
Akira Abe
view source
Akira Abe
view source
Akira Abe
view sourceYoutube
Googleplus
Akira Abe
Akira Abe (Step1Up)
Akira Abe
Akira Abe
Akira Abe
Akira Abe
Akira Abe
Akira Abe
Get Report for Akira Abe from Ann Arbor, MI, age ~71